c-Met inhibitors

c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Mughal, Anum, Aslam, Hafiz Muhammad, Sheikh, Asfandyar, Khan, Agha Muhammad Hammad, Saleem, Shafaq
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626853/
https://www.ncbi.nlm.nih.gov/pubmed/23566349
http://dx.doi.org/10.1186/1750-9378-8-13
_version_ 1782266256510943232
author Mughal, Anum
Aslam, Hafiz Muhammad
Sheikh, Asfandyar
Khan, Agha Muhammad Hammad
Saleem, Shafaq
author_facet Mughal, Anum
Aslam, Hafiz Muhammad
Sheikh, Asfandyar
Khan, Agha Muhammad Hammad
Saleem, Shafaq
author_sort Mughal, Anum
collection PubMed
description c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. Met inhibitors divided into two main classes: class I (SU-11274-like) and class II (AM7-like). The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors might be used in combination with other treatments, including chemo-, radio- or immunotherapy
format Online
Article
Text
id pubmed-3626853
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36268532013-04-16 c-Met inhibitors Mughal, Anum Aslam, Hafiz Muhammad Sheikh, Asfandyar Khan, Agha Muhammad Hammad Saleem, Shafaq Infect Agent Cancer Letter to the Editor c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. Met inhibitors divided into two main classes: class I (SU-11274-like) and class II (AM7-like). The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors might be used in combination with other treatments, including chemo-, radio- or immunotherapy BioMed Central 2013-04-08 /pmc/articles/PMC3626853/ /pubmed/23566349 http://dx.doi.org/10.1186/1750-9378-8-13 Text en Copyright © 2013 Mughal et al.; http://creativecommons.org/licenses/by/2.0 licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Mughal, Anum
Aslam, Hafiz Muhammad
Sheikh, Asfandyar
Khan, Agha Muhammad Hammad
Saleem, Shafaq
c-Met inhibitors
title c-Met inhibitors
title_full c-Met inhibitors
title_fullStr c-Met inhibitors
title_full_unstemmed c-Met inhibitors
title_short c-Met inhibitors
title_sort c-met inhibitors
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626853/
https://www.ncbi.nlm.nih.gov/pubmed/23566349
http://dx.doi.org/10.1186/1750-9378-8-13
work_keys_str_mv AT mughalanum cmetinhibitors
AT aslamhafizmuhammad cmetinhibitors
AT sheikhasfandyar cmetinhibitors
AT khanaghamuhammadhammad cmetinhibitors
AT saleemshafaq cmetinhibitors

Ejemplares similares